Results 31 to 40 of about 278,985 (182)
Nature Communications, 2020 Dopamine agonists increase brain glutathione levels. Here the authors identify noncanonical signalling by Nrf2 as a potential mechanism for the neuroprotective effects of dopamine D2 receptor activation.
Yao Wei +11 more
doaj +1 more source
Endocrine Connections, 2018 The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population.
Anastasia P Athanasoulia-Kaspar +2 more
doaj +1 more source
Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Frontiers in Psychiatry, 2022 Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists.
Ana Carolina Correa e Castro +7 more
doaj +1 more source
Dopamine agonists delayed or missed dosages (n = 213).
, 2015 Dopamine agonists delayed or missed dosages (n = 213).
John P. Chapman (725861) +8 more
core +1 more source
TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
Frontiers in Pharmacology, 2018 Trace-amine associated receptor 1 (TAAR1) is the best-characterized member of the family of TAARs. TAAR1 is broadly expressed in the brain, especially within the monoaminergic systems.
Jian-Feng Liu, Jian-Feng Liu, Jun-Xu Li
doaj +1 more source
Dopamine Agonists: From the 1970s to Today
, 2019 The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting ...
DE ALCUBIERRE, DARIO +5 more
core +1 more source
Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
Frontiers in Endocrinology, 2018 Introduction: Prolactinomas are preferentially treated with dopamine agonists. However, a few adenomas are resistant to this treatment.Objective: To evaluate the characteristics of patients with resistance to dopamine agonists in the long-term.Method: A ...
Maria de Fátima de Magalhães Gonzaga +11 more
doaj +1 more source
Dopamine receptor agonists and sleep disturbances in Parkinson's disease
, 2009 Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated.
Logishetty, Kartik +3 more
core +1 more source
Dopamine-Agonist Induced Cerebrospinal Fluid Rhinorrhea; a Case Report
Journal of Cancer and Allied Specialties, 2021 Introduction: Prolactinomas are the most common pituitary adenomas. Medical therapy with dopamine agonists (DA) is the mainstay of treatment and rarely requires surgical manipulation.
Hira Irfan +5 more
doaj +1 more source
Dopamine receptor subtypes and ingestive behaviour [PDF]
, 1999 Both centrally and systemically administered dopamine agonists and antagonists decrease ingestive behaviour. The aim of this thesis was to examine whether drugs acting at different receptor subtypes decreased intake in different ways.
Genn, Rachel F., Genn, R.F.
core